Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Nat Genet. 2013 Jun 2;45(7):747–755. doi: 10.1038/ng.2650

Figure 5. Synergistic effect of ADT and embelin, in mouse CRPC.

Figure 5

(a) Weight of VP, DLP, and AP of Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre and Ptenflox/flox;p53flox/flox;Probasin(Pb)-Cre mice treated with bicalutamide (Casodex) (n=8) (black bars) or bicalutamide plus embelin (n=8) (grey bars) for 4 weeks. Data are presented as mean ± standard deviation. (b-e) Proliferation rate analysis as percentage of Ki67 positive cells in VP, DLP, and AP of the samples described in a. Data are presented as mean ± standard deviation. (f-g) H&E and apoptosis analysis through Western blot quantification of Parp cleavage versus total Parp in VP, DLP, and AP of the Ptenflox/flox;Lrfflox/flox;Probasin(Pb)-Cre prostate cancers described in a.